L3VLUP
ProSign in

MRNA · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MRNAGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MRNA
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterMRNAGILD
Q3 20206 holders, $3.1bn25 holders, $14.2bn
Q4 202016 holders, $4.4bn27 holders, $13.4bn
Q1 202118 holders, $8.0bn24 holders, $14.5bn
Q2 202122 holders, $18.4bn18 holders, $14.9bn
Q3 202127 holders, $27.6bn20 holders, $16.4bn
Q4 202120 holders, $17.2bn20 holders, $16.8bn
Q1 202216 holders, $11.8bn28 holders, $13.2bn
Q2 202219 holders, $10.2bn26 holders, $13.6bn
Q3 202222 holders, $8.4bn24 holders, $13.3bn
Q4 202220 holders, $13.0bn32 holders, $21.1bn
Q1 202317 holders, $11.2bn27 holders, $21.8bn
Q2 202315 holders, $8.9bn24 holders, $20.7bn
Q3 202312 holders, $7.2bn24 holders, $20.0bn
Q4 20238 holders, $6.9bn22 holders, $21.5bn
Q1 20247 holders, $7.6bn30 holders, $20.3bn
Q2 202413 holders, $9.5bn28 holders, $18.5bn
Q3 202412 holders, $4.8bn29 holders, $24.2bn
Q4 202415 holders, $3.1bn28 holders, $25.9bn
Q1 202511 holders, $2.0bn33 holders, $32.0bn
Q2 202510 holders, $2.0bn27 holders, $30.9bn
Q3 20259 holders, $1.2bn23 holders, $29.4bn
Q4 202510 holders, $2.5bn25 holders, $34.3bn
Q1 20269 holders, $4.8bn25 holders, $38.5bn
Q2 20269 holders, $8.0bn26 holders, $34.2bn
MRNA

Moderna Inc

Holders
7
Reported value
$7.6bn
Buyers
3
Sellers
5

Breadth -2 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
30
Reported value
$20.3bn
Buyers
17
Sellers
12

Breadth +5 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2024

Among the 33 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MRNA (3)

ARK Investment Management LLC, Baillie Gifford & Co, PDT Partners LLC

Only GILD (26)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Hudson Bay Capital Management LP, Janus Henderson Group Ltd, Man Group PLC, Neuberger Berman Group LLC, Point72 Asset Management LP, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Winton Group Ltd, and 1 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →